Abel Hall LLC Purchases 40 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Abel Hall LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 522 shares of the pharmaceutical company’s stock after purchasing an additional 40 shares during the quarter. Abel Hall LLC’s holdings in Vertex Pharmaceuticals were worth $210,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Northwest Investment Counselors LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at about $25,000. Dunhill Financial LLC grew its position in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the period. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $27,000. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $33,000. Finally, Truvestments Capital LLC bought a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $35,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on VRTX shares. Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Citigroup assumed coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 target price on the stock. Stifel Nicolaus increased their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Monday, January 13th. Finally, Truist Financial lowered their target price on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $494.76.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $441.52 on Thursday. The company has a market cap of $113.70 billion, a PE ratio of -221.87, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. The firm has a 50-day moving average of $434.75 and a 200-day moving average of $463.64. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter last year, the company posted $3.67 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.